BIOWAIVER STUDY OF IMMEDIATE RELEASE GLIMEPIRIDE TABLETS

SIHAM ABDOUN1, DALIA GABER1*, RAGHAD ALWAHABI2, NASHWA ALQUSSIR2, NEHAL ALMUTAIRI2, WAAD ALSALAMAH2

1Department of Pharmaceutics, College of Pharmacy, Qassim University, Buridah, KSA, 2Pharm D candidate, College of Pharmacy, Qassim University, Buridah, KSA

Email: dr.daliaahmed@hotmail.com

Received: 13Aug 2020, Revised and Accepted: 21Oct 2020

ABSTRACT

Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among innovator products and generics is a key step in permitting the marketing of generic products. The study aimed to evaluate the bioequivalence of five different generic brands of Glimepiride tablets under biowaiver conditions.

Methods: The quality of the tablet products, including uniformity of weight, friability, and disintegration test, was assessed using the United State Pharmacopeia (USP) general monograph for the tablet dosage form. The content of glimepiride in the tablets was measured using UV spectrophotometer at the wavelength 229 nm. The release of Glimepiride from the tested and originator tablet products was evaluated using the dissolution profiles conducted in HCl buffer pH 1.2, and phosphate buffer pH 6.4 and 7.8 by USP dissolution apparatus II. The bioequivalence of test products was assessed using the similarity and difference factors.

Results: The tested products complied to USP requirements for quality standards; all the products show rapid disintegration, D1 show higher time (Three minutes) while D3 show lower time (28 seconds). The content of test products was (104.68, 93.75, 97.21, 97.03, and 102.10) for D1, D2, D3, D4 and D5, respectively, compared to 103.70 for OB. Dissolution profiles revealed that the highest similarity to the originator was showed in pH 6.4; f2 ranged (74.5-68.4) for all the tested products and low similarity in pH 7.8; f2 ranged (45.2-64.7).

Conclusion: The study showed that the generic products has noticeable similarity with the originator brand and it can be interchangeable.

Keywords: Dissolution, Glimepiride, Bioavailability, Biowaiver, Generic drugs, Originator

INTRODUCTION

Demonstrating therapeutic equivalency regarding the efficacy and safety among innovator and generic products is a key step in permitting the marketing of generic products [1, 2]. Bioavailability studies directed in animals and/or humans are considered as time and money consuming steps in the developing of a new pharmaceutical product [3, 4]. Using of dissolution tests can be considered as a substitute for in vivo bioavailability studies. It is a cheaper, easier, and less time-consuming test, consequently, it is used as substitute to in vivo studies [4, 5]. Generic products are varying in their bioavailability due to variation in manufacturing processing condition, type of formulation and techniques used; moreover, they must be equivalence to the innovator, so the regulatory authority required in vivo bioavailability study to ensure the equivalence of generic products [1-3] but these studies are expensive and take a long time, in order to minimize the number and type of bioequivalence studies that have to be carried out. The World Health Organization (WHO), International Council for Harmonization (ICH), and Food and Drug Administration (FDA) suggest waiver of in vivo bioequivalence studies using in vitro release dissolution data for immediate release oral solid dosage form based on Biopharmaceutical Classification System (BCS) [1, 6-11]. BCS is based on waiving bioequivalence studies depending on the solubility and gastrointestinal permeability of drug substance and it use for generic products development by manufacturer as it save time and resources [1]. For registration of generic products it is required that a bioequivalence study must be provided to indicate generic product is equivalent to innovator one that must be with same active ingredient, same dosage forms, and strength, in order to submit for marketing authorization[12]. Biowaiver studies are conducted to evaluate the therapeutic equivalence of two or more products alternative to the in vivo testing [13-16]. In addition, to determine the conditions required for the dissolution test [17, 18]. Glimepiride is an oral sulfonylurea agent for the treatment of type 2 diabetes mellitus it causes a decrease in blood glucose by inducing insulin secretion from β cells in the pancreas and by increasing peripheral tissue sensitivity to insulin [19]. Glimepiride available as an oral dosage form and completely absorbed from GIT After administration [20]. The peak plasma concentrations (Cmax) will reach in 2 to 3 h; it possess highly plasma protein-bound (PPB) approximately 99.5% [21]. It has a half-life around 5 to 8 h, which may increase with multiple doses up to 9 h; hence these factors contribute to an inconsistent profile of dissolution and absorption, and hence variations in bio-availability and drug action [22, 23]. The biopharmaceutical characteristic of Glimepiride is described as low solubility in aqueous media and high permeability in gastrointestinal tracts. The drug shows low, pH-dependent solubility. So, based on studied biopharmaceutical data, Glimepiride could be classified into BCS Class II [24]. According to WHO, biowaiver procedure available in Class II [highly permeable and poorly soluble] when rapidly dissolving (release of>85% of the labeled amount of drug in 30 min), [25]. Glimepiride displays pH-dependent solubility. The drug is extremely poorly soluble in acid and neutral media. On the other hand, the solubility of drugs is slightly raised to (0.02) mg/ml in alkaline media with pH>7 [26].

The study aimed to evaluate the bioequivalence of five different generic brands of Glimepiride 3 mg tablets under biowaiver conditions, in vitro dissolution test were conducted for five generic products of Glimepiride immediate-release tablet in the market mentioned as D1, D2, D3, D4 and D5 in comparison to Originator brand [Amaryl® 3 mg] in three different pH media HCl buffer pH 1.2 and phosphate buffer pH 6.4 and 7.8.

MATERIALS AND METHODS

Materials

Reference Glimepiride was a kind gift sample from (Tabouk Co., KSA). Four generic brands of Glimepiride 3 mg tablets market in KSA named D1, D2, D3, and D4 and the Originator brand (OB) Amaryl® 3 mg [Sanofi S p. An Italy] was purchased from a registered pharmacy.
Hydrochloric acid (LobaChemie Pvt. Ltd, India), potassium chloride (Avonchem limited, UK), potassium dihydrogen orthophosphate (LobaChemie Pvt. Ltd, India), sodium hydroxide (May and Baker LTD, Bahanem, England) Potassium Chloride (AVONCHEM limited), methanol (Sigma-Aldrich, USA).

Characterization of physiochemical parameters
Physiochemical properties of the tablet products, including uniformity of weight, friability, disintegration test, and drug content, were assessed according to United State Pharmacopeia (USP) standard for the official test and to the manufacture specification to non-official tests [27].

Preparation of different buffer media
The buffer media used in the study are HCl buffer pH 1.2 and phosphate buffer pH 6.4 and 7.8 were prepared according to USP [27].

Ultraviolet scanning of glimepiride in different pH buffer media
Stock solutions of glimepiride in methanol were prepared and serial dilution was made using the three previously mentioned buffer media. The spectrum of these solutions was run using a spectrophotometer at 200-400 nm to determine the maximum absorption wavelength (λ max).

The precision of the method was verified by inter-day and intra-day variation studies.

Preparation of standard calibration curves
A concentration ranged between 2-20 μg/ml of Glimepiride standard was prepared from stock solutions using methanol and the buffer system, using Ultra-violet spectrophotometric method at the predetermined maximum wavelength, the absorption of these solutions were measured and lines of regression were plotted. The calibration made in methanol was used for content determination while that in HCl buffer pH1.2 and phosphate buffer pH 6.4 and 7.8 were used for the dissolution studies of the sample tablets.

Drug content assay
Ten tablets from each brand were randomly selected and weighted to obtain the average. The tablets were crushed to powder using mortar and pestle, an exact quantity of the powder equivalent to 10 mg glimepiride was weighed and transferred to a 100 ml volumetric flask and diluted with methanol to 100 ml, the resulting solution was filtered using Whatman filter paper, 5 ml of the filtrate was transferred to 50 ml volumetric flask and diluted with methanol to 50 ml, a concentration of 0.001% w/v of glimepiride was obtained. The resulting solution was measured at 229 nm using UV/visible spectrophotometer at 229 nm. The percentage release was calculated using the calibration standard curve. The results were declared as the percentage of the cumulative amount of drug released versus time [29].

Analysis of data
Simple statistics measurement (mean±standard deviation) was used to analyze data of weight variation, diameter, thickness, friability, drug content, and disintegration. The dissolution profile differences were assessed based on the similarity factor (f2) and the difference factor (f1) as:

\[ f_2 = 50 \times \log \left(1 + \frac{1}{n} \sum (Rt - Tt)^2 \right) - 0.5 \times 100 \]

\[ f_1 = \frac{1}{n} \sum |Rt - Tt| + 100 \]

f1 value of 0 to 15 confirms a slight difference between the two products[7, 30].

RESULTS AND DISCUSSION
Physical characteristics evaluation
Five generic brands D1, D2, D3, D4 and D5 of Glimepiride 3 mg immediate-release tablets were studied in comparison to the Originator Brand (OB). The quality test conducted was; tablet weight variation, friability, and disintegration, all products comply with the pharmacopeial standards of tablet dosage forms. The uniformity of weight test was conducted to ensure the uniformity of weight, which reveal the content uniformity also the test indicates the appropriate size of tablets [31]. All tested tablets showed a percentage weight variation within the range of 7.5% and thus it meets the USP Pharmacopeia standards specification of weight variation and the quality control test [32]. Friability test is conducted to assess the capability of the tablet to withstand mechanical stress during manufacturing, packaging and transportation, which lead to physical defect in tablets like capping, chipping, abrasion and breaking. Therefore, it is essential for tablets to withstand such stress. The USP stated that the loss of weight due to friability should be less than 1%, all the test products were within this standard. D3 and D5 showed the lowest loss in weight (0.09% and 0.11) respectively followed by D1 and D4 (0.12 and 0.14) respectively; which revealed their capability to withstand mechanical stress. Tablets disintegration is the break down of tablet to small particles and it is one of the most important indications of dissolution and hence bioavailability of products [33, 34]. The disintegration time of all tested products were within a specified time of less than 15 min for uncoated tablets, which will be influenced on the dissolution. All the generic and originator products disintegrate in time less than 1 minute to 3 min, with highest disintegration time obtained by generic D1 (300 min) which will reveal in better release (table 1).

Table 1: Physical characteristics evaluation of selected generic brands of tablets in comparison to originator brand [OB]

| Brand | Colour and shape | *Thickness (mm),**n=10 | *Diameter (mm),**n=10 | *Uniformity of weight[mg] **n=20 | Friability (%) **n=10 | *Disintegration min,** n=6 |
|-------|------------------|------------------------|------------------------|-----------------------------|----------------------|--------------------------|
| D1    | Pink, Oblong with break | 2.62±0.32 | 5.53±0.06 | 157.35±1.22 | 0.12 | 3.0±0.36 |
| D2    | Of white, Oblong with Break | 3.13±0.02 | 5.19±0.03 | 166.15±1.32 | 0.36 | 0.2±0.83 |
| D3    | Of white, Oblong with Break | 4.20±0.01 | 5.48±0.04 | 148.5±0.73 | 0.09 | 2.1±0.31 |
| D4    | Of white, Oblong with Break | 4.47±0.01 | 5.62±0.06 | 223.9±1.72 | 0.14 | 2.1±0.11 |
| D5    | Of white, Oblong with Break | 3.12±0.01 | 6.53±0.048 | 172.9±1.89 | 0.11 | 0.3±0.10 |
| OB    | Of white, Oblong with Break | 2.32±0.025 | 5.7±0.32 | 166.35±1.15 | 0.24 | 1.2±0.07 |

* Results expressed as mean±SD, ** n= number of sample
Spectrum of glimepiride in different pH media

Spectrums scan for Glimepiride standard solution in three different pH mediums 1.2, 6.4, and 7.8 were performed in a range between 200-400 nm. It showed a maximum wavelength absorption ($\lambda_{max}$) at 229 nm for all media as shown in fig. 1.

Calibration curve for glimepiride in the three buffer media

Glimepiride standard solution in the HCl buffer system pH 1.2 and phosphate buffer pH 6.4 and 7.8 show linearity in the concentration range 2-20 µg/ml as detected by linearity equation and regression as shown in fig. 2.

Fig. 1: UV spectrum scan for glimepiride standard in pH 6.8 medium

Fig. 2: Calibration curve of glimepiride standard in three buffer system, *where y and x are the absorbance and the concentration, respectively

Fig. 3: Drug content of glimepiride tablets, *results expressed as mean±SD, sample size= 3
Drug content assay

The content uniformity results are shown in fig. 2. All tablet samples were complying with pharmacopeial limits, i.e., the percentage average drug content of all samples were (104.68, 93.75, 97.21, 97.03, and 102.10) for D1, D2, D3, D4, and D5, respectively compared to 103.70 for OB. All results within the USP standard range of 90% to 110% of the label statement amount.

Dissolution studies

In vitro dissolution profiles comparison was conducted to ensure quality equivalence and approval of generic formulations in HCl buffer pH 1.2 and phosphate buffer pH 6.4 and 7.8. Compared to the reference product, the dissolution profile and percent release in 60 min for each tablet in the three buffer system is shown in fig. 3-5. The similarity factor f2 and difference factor f1 are calculated in the three buffer system in comparison with the originator brand.

In the hydrochloric acid buffer media pH 1.2 all generic brands D1, D2, D3, D4, and D5 met originator requirement with similarity factor 60.0, 55, 57.67, 60.64 and 59.93, respectively. The difference factors were 4.69, 6.81, 4.14, 3.97 and 3.09 respectively in addition all the products release more than 85% of the active ingredient in 15 min, so they passed the WHO requirement of rapidly dissolving and met the bioequivalence criteria.

In contrast, the release of the drug in phosphate buffer pH 6.4 revealed that all products meet the WHO requirements. As the similarity factor of all products more than 50 (74.5, 74.0, 68.5, 66.4 and 68.5 respectively) and the f1 values are less than 15 for all products. The release of the active pharmaceutical ingredient from OB, D1, D2, D3, D4, and D5 in phosphate buffer pH 6.4 and 7.8 is more than 85% in 15 min which indicates the fulfillment of WHO bioequivalence criteria however the similarity factor of D1; in phosphate buffer pH7.8 is less than 50 and for the other products about 50 which revealed poor bioequivalence of D1 generic drugs compare to the originator in contrast to D5 show high similarity factor which may be due to the type of excipient and manufacturing process. From the results of dissolution profile in this study it observable that the generic drugs is mostly similar to the originator one in all buffer media specially phosphate buffer pH 6.4, and it released more than 85% of API in 15 min and crossed similarity factor in all pH medium so it can be considered as bioequivalent with the OB under experiment conditions. The dissolution profiles of different products under investigation did not show correlation between the strength and dissolution of tablets. ANOVA test results showed that different tablets had different strengths (p<0.01). OB and D2, which had different strength values (fig. 3), had more than 85% of the drug released within 15 min, which revealed the finding that not only content of drugs and the manufacturing conditions, affect drug release but also formula factors, such as disintegrates and diluents types play an important part in the disintegration of tablet and dissolution profiles. Based on bioequivaer study results, D1 sample in pH 7.8 is not bioequivalent with the OB unless further an in vivo bioequivalent studies prove that it comparable to Reddy, N. H., et al., finding that some but not all Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride products met the bioequivaer criteria [35]. Excipients and additives used in manufacturing tablets have great effects on their dissolution, therefore to achieve bioequivaer according to regulatory rules, good manufacturing practice should be followed and careful selection of the excipients used is mandatory.

![Fig. 4: Dissolution profiles of OB, D1, D2, D3, D4 and D5 tablets at pH 1.2 dissolution medium (n=3, mean±SD)](image)

![Fig. 5: Dissolution profiles of OB, D1, D2, D3, D4 and D5 tablets at pH 6.4 dissolution medium (n=3, mean±SD)](image)
This research received no external funding.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICTS OF INTERESTS

The authors declare no conflict of interest.

REFERENCES

1. Mishra V, Gupta U, Jain N. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies, Pharmazie 2010;65:155–61.
2. Kalantzis I, Reppas C, Dressman JB, Amidon G, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen [paracetamol]. J Pharm Sci 2006;95:54–14.
3. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate and chloroquine hydrochloride. J Pharm Sci 2005;94:1389–95.
4. Potthast H, Dressman JB, Junginger HE, Midha KK, Oesser H. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci 2005;94:2121–31.
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennerna H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85–96.
6. Korterwar H, Yipertula M, Dressman JB, Junginger HE, Midha KK, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sci 2005;94:1617–25.
7. FDA. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Food and Drug Administration, Center for Drug Evaluation and Research. USA; 2000. Available from: http://www.fda.gov/cder/guidance/3618fnl.pdf. [Last accessed on 10 Jul 2020]
8. The Biopharmaceutics Classification System (BCS) Guidance. Available from: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128219.htm. [Last accessed on 10 Jul 2020]
9. WHO. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Working document AS/04.093/Rev.4. World Health Organization; 2005. Available from: http://www.who.int/medicines/services/expertcommittees/pharmprep/QA/S04_093Rev4_final.pdf [Last accessed on 10 Jul 2020].
10. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biowaiver: an alternative to bioavailability. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen [paracetamol], ibuprofen, ranitidine hydrochloride. J Pharm Sci 2006;95:54–14.
11. Bergstrom CA, Luthman K, Artursson P. Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharm Sci 2002;19:921–5.
12. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2005;60:265–8.
13. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11–23.
14. The Merck Index, Version 12.1 on CD-ROM. Merck and Co., Whitehouse Station, NJ, USA; 1996. p. 1151-63.
15. Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. Biowaiver monographs for immediate-release solid oral dosage forms: primaqnine phosphate. J Pharm Sci 2012;101:936-45.
16. Hassan HA, Charoo NA, Ali AA, Alkhateem SS. Establishment of bioequivalence indicating dissolution specification for candesartan cilexetil tablets using a convolution model. Dissolution Technol 2015;22:38-45.
17. Qureshi SA. In vitro-in vivo correlation (IVIVC) and determining drug concentrations in blood from dissolution testing—a simple and practical approach. Open Drug Delivery J 2010;4:38-47.
18. Blume EL, Schug BS. The biopharmaceutical classification system (BCS): class III drugs better candidates for BA/BE waiver? Eur J Pharm Sci 1999;9:117–21.
19. Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123:S12-8.
20. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations. Vasc Health Risk Manag 2012;8:463-72.
21. Drug Approval Package. Amaryl® (Glimepiride) NDA# 20-4965-002. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020496S002.cfm [Last accessed on 10 Jul 2020]
22. Massi Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003;25:799-816.
23. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015;11:840-8.
24. Das IJ, Deepti R, Rajashekar Y, Samal HB. Design and characterization of glimepiride fast-dissolving tablets. Int J PharmTech Res 2015;8:1-1.
25. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series, No. 937, Annex 8. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. World Health Organization: Geneva; 2006.
26. Vidhyadhara S, Babu JR, Sasidhar RL, Ramu A, Prasad SS, Tejasree M. Formulation and evaluation of glimepiride solid dispersions and their tablet formulations for enhanced bioavailability. Pharmaceut Anal 2011;4:15-20.
27. Pharmacopeia, U. S. "35/National Formulary 30." Rockville, MD: US Pharmacopeial Convention, Inc; 2012.
28. Rowe R, Sheske P, Weller P. Handbook of pharmaceutical excipients. In: Rockville MD. Asian edition; 2000. p. 843-65.
29. World Health Organization. Guidance on waiver of in vivo bioequivalence requirements. Available from: http://apps.who.int/medicines/docs/documents/s23056en/s23056en.pdf. [Last accessed on 08 Sep 2019]
30. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001;220:77-83.
31. Yoshida I, Sakai Y. The applications of the content uniformity test and the weight variation test on process validation tests of multiple ingredient preparations. Chem Pharm Bull 1999;47:678-83.
32. Nishat N, Muhammad A, Rumana M, Farhana R, Ashiqul A. A comparative study of physical parameters of selected ketorolac tromethamine tablets available in the pharma market of Bangladesh. J Appl Pharm 2011;8:101-3.
33. Aulton ME, Taylor K. Aulton’s pharmaceutics: the design and manufacture of medicines. 4th ed. New York: Churchill Livingstone Elsevier; 2013.
34. Niazi SK. Handbook of bioequivalence testing. 1st ed. New York: Informa Healthcare; 2007.
35. Reddy NH, Patnala S, Kanfer I. Investigation of bio waivers for immediate release formulations containing BCS III drugs, acyclovir, atenolol, and ciprofloxacin hydrochloride, using dissolution testing. AAPS PharmSciTech 2017;18:42-4-31.